OP-1250 is an orally bioavailable CERAN currently in phase I/II open-label, multi-center, dose-escalation and expansion clinical trial (NCT04505826) for the treatment of ER+ advanced BC and/or MBC [117,118]. This evidence concerns the gene ESR1 and breast cancer.